A Study of Effect of Different Biochemical Markers including Leptin and Spexin in Children Before and After Having Hypothalamus Surgery

Overview

Información sobre este estudio

The purpose of this study is to learn more about the changes in levels of Spexin, leptin and other biomarkers such as adiponectin and resting energy expenditure before and after hypothalamic surgery.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria 

Children with Hypothalamic Ovesity:

  • History of a tumor in the sellar/suprasellar region with hypothalamic involvement
  • Age 2-17 years
  • Stable hormone replacement therapy for more than 6 months (with levothyroxine, glucocorticoids and sex steroids)

Control Samples:

  • Patients with simple obesity who have previously participated in a clinical trial aimed at studying the effect of vitamin-D supplementation on insulin action
  • Age 12-18 years

Exclusion Criteria: 

  • Untreated pituitary dysfunction except for untreated growth hormone deficiency
  • Type 1 or 2 diabetes mellitus
  • Previous (within 6-months) or current use of weight loss medication
  • Previous (within 6-months) or current use of drugs associated with weight gain (e.g. steroids/anti-psychotics)
  • Previous bariatric surgery
  • Recent initiation (within 3-months) of anti-hypertensive or lipid medication
  • Obesity associated with genetic disorder (monogenetic obesity)

Control Samples:

  • Hepatic or Renal disorders.
  • Type 1 or Type 2 diabetes mellitus.
  • Ongoing use of insulin, metformin, or oral hypoglycemic medications.
  • Malabsorption disorders (celiac disease, cystic fibrosis, and inflammatory bowel disease.
  • Serum 25(OH) D > 100 ng/mL, and serum calcium > 10.8 mg/dL.
  • Use of glucocorticoids or anti-seizure medications in the preceding 6 months, ongoing multivitamin supplementation

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Aida Lteif, M.D.

Cerrado para la inscripción

Contact information:

Aida Lteif M.D.

(608)392-9882

Lteif.Aida@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20304191

Mayo Clinic Footer